Cancer Biomarker Testing Market by Type Of Cancer (Cervical cancer, Lung Cancer, Collateral Cancer, Liver Cancer, Prostate Cancer, Breast Cancer, Others) and Application (Drug Discovery and Development, Personalised Medicine, Diagnosis, Others) End-User (Hospitals, Cancer diagnostic Centres, Research Institutes, Others)- Geography


Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Cancer Biomarker Testing Market was valued at USD 10.42 billion in 2021 and is anticipated to grow at USD 20.59 billion by 2028 recording a CAGR of 12.4% during the forecast period 2022-2028. The cancer biomarker test market is driven by rising prevalence of cancer worldwide. World Health Organization (WHO) stated that cancer is one of the leading causes of mortality and morbidity worldwide, with approximately 14 Mn new cases in 2012. The number of new cases is expected to rise about 70% over the coming 2 decades. In addition, increase in awareness in public and healthcare professionals regarding early diagnostic procedures, rise in government and NGO’s funding for oncology are expected to bolster the cancer biomarker testing market. Furthermore, the development of companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the cancer biomarker test market. However, high cost for biomarker tests, low detection rates and regulatory policies are expected to hamper the cancer biomarker test market. The global market is expected to grow with significant CAGR during forecast period. Market players are carrying out collaborations, partnerships, and acquisitions as key development strategies to enhance the market share. For instance, in March 2017, Foundation Medicine and Bristol-Myers Squibb entered collaboration to understand tumour profile and its microenvironment to predict patient's response to cancer immunotherapy. Using Foundation Medicine's foundation genomic profiling assay, the firm will look at tumour mutational burden and microsatellite instability in patients enrolled in clinical trials for Bristol-Myers Squibb (BMS) cancer drugs. For instance, in October 2016, Arquer Diagnostics Ltd. (Arquer), and University of Sunderland are collaborated to investigate noninvasive specimen preparation techniques that will facilitate the use of Arquer’s MCM5-ELISA test in a wide range of cancers. In April 2016, Stemcentrix acquired by AbbiVe along with its lead late stage biomarker rovalpituzumab tesirine (Rova-T), that helps to identify tumour cells. In 2015, Abbot Laboratories acquired exclusive rights for FGFR3 gene mutations to detect bladder cancer. FGFR3 developed at Institute Curie, it is a gene mutation and useful for early detection, disease monitoring, and prognosis of bladder cancer through tissue and urine-based testing.  

Global Cancer Biomarker Testing Market Summary

Study Period


Base Year




Largest Market

North America

Fastest Growing Market

Cancer Biomarker Testing Market Dynamics

Companion diagnostics, tailored medications, and other disease diagnostics, such as disease risk assessment and drug research and development, all rely heavily on cancer biomarkers. One of the primary reasons likely to boost cancer biomarkers market growth during the projected period of 2021-2027 is the increased utilisation of biomarkers in disease diagnosis. The rising global prevalence of cancer is driving the need for early disease detection, which is propelling the market forward. According to the National Cancer Institute, 1,735,350 new cancer cases were reported in the United States in 2018. In addition, the World Cancer Research Fund International estimates that 18.0 million individuals worldwide were affected by cancer in 2018. Lung and breast cancers were the most prevalent cancers reported globally in 2018, accounting for 12.3 percent of all cases diagnosed. The increased incidence of cancer biomarkers in both developing and developed countries is expected to boost demand for cancer diagnostics and therapy. During the projection period of 2021-2027, these factors are expected to boost demand for these biomarkers. Despite the rising global incidence of cancer and the increasing number of patients requiring diagnostic tests, the lack of reimbursement regulations for biomarker tests in emerging and industrialised nations is one issue restricting global demand for these biomarkers. Another key stumbling block to the market’s expansion is the high cost of cancer diagnosis and treatment in developing countries. This is reducing the number of patients who are tested for biomarkers, and patients are increasingly preferring other low-cost detection tests.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Cancer Biomarker Testing Market Segmentation

type of cancer
  • Cervical cancer
  • Lung Cancer
  • Collateral Cancer
  • Liver Cancer
  • Prostate Cancer
  • Breast Cancer
  • Others
  • Drug Discovery and Development
  • Personalised Medicine
  • Diagnosis
  • Others
By End User
  • Hospitals
  • Cancer diagnostic Centres
  • Research Institutes
  • Others
By Geography
North America
  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe
  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific
Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
Middle East and Africa (MEA)
  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

Frequently Asked Questions

The cancer biomarker testing market is projected to expand at a CAGR of 12.4% during the forecast period.  

Thermo Fisher Scientific  (Affymetrix Inc.), Abbott Laboratories, F. Hoffmann-La Roche Ltd., AbbVie Inc.Arquer Diagnostics Ltd., Illumina, Inc.

North America is the fastest-growing region for cancer biomarker testing market

[urltag url='request-table-of-content']

  • Thermo Fisher Scientific  (Affymetrix Inc.) (U.S.)
  • Abbott Laboratories (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • AbbVie Inc. (U.S.)
  • Arquer Diagnostics Ltd. (U.K.)
  • Illumina, Inc. (U.S.)
  • Qiagen (Germany)
  • Agilent Technologies (U.S.)
  • Merck & Co. Inc. (U.S.)
  • Becton Dickinson and Company (U.S.)
  • Hologic Inc. (U.S.)